Stonegate Capital Partners Updates Coverage on Cingulate Inc., Highlights CTx-1301 ADHD Treatment Progress
Stonegate updates coverage on Cingulate's ADHD drug CTx-1301, highlighting FDA manufacturing focus, $23M cash position, and $250M revenue potential in ADHD market
2026/04/07